MA-VERACODE
21.4.2022 17:52:05 CEST | Business Wire | Press release
Veracode , a leading global provider of application security testing (AST) solutions, today announced it has been positioned as a Leader for the ninth consecutive time in the 2022 Gartner Inc. Magic Quadrant for Application Security Testing1 . The company is the only vendor recognized as a Leader every single year since the report was first published.
“Since Veracode launched in 2006, we have played a significant role in shaping the application security market,” said Sam King, Chief Executive Officer at Veracode. “To be recognized as a Leader every single year, in our opinion, is a validation of our rich heritage, continued innovation, and strong vision for the future of software security and development. With cybersecurity taking center stage for enterprises across all industries, we’re proud to be a trusted partner for our customers, enabling them to bring development and security teams together to build and deliver secure software at the speed that business demands.”
According to Gartner, Veracode is recognized for its completeness of vision and ability to execute in the AST market. The company has also been identified in Gartner Peer Insights™ as a Customers’ Choice for Application Security Testing 2 , which is based on feedback and ratings from independent customer reviews.
Brian Roche, Chief Product Officer at Veracode, said, “The rapid acceleration of digital transformation, combined with increased software supply chain complexity and new cybersecurity regulations, means software security has never been more vital. Over the past year, we have focused heavily on geographical expansion with our European Region instance, and delivered new technologies, such as API Scanning, that address some of our customers’ biggest pain points. Our own platform evolution initiatives give us a deep understanding and appreciation for the challenges many of our customers face in their own digital transformation journeys, improving our capacity to function as a trusted advisor.”
Veracode’s comprehensive platform offers multiple testing types and integrates into popular development tools through a frictionless interface, providing a 360-degree view of application security posture. The company credits its position in the report to a laser focus on the transformation of its platform, launch of API Scanning, authentication management in dynamic analysis, and its static analysis and software composition analysis (SCA) capabilities Veracode’s SCA product uses natural language processing and machine learning to accurately identify vulnerabilities from multiple sources in open-source libraries. Through this proprietary process, the Veracode solution has identified hundreds of previously undetected vulnerabilities in open-source libraries in the last year alone.
In 2021, Veracode launched the Veracode European Region instance to support EU data residency requirements. The underlying platform has been leveraged to underpin Veracode’s much-anticipated FedRAMP instance, which will be introduced in the coming months.
“It’s a truly exciting time for Veracode. We have just announced a significant growth investment from TA Associates with a $2.5 billion valuation—a major milestone in our 16-year history—and look forward to a year of continued innovation and accelerating growth. We remain tirelessly committed to our mission of securing the software that powers our customers’ businesses, and our continued position as a Leader is, in our opinion, a testament to the passion and dedication of our team around the world,” King added.
To download a complimentary copy of the full 2022 Gartner Magic Quadrant Report, visit: https://info.veracode.com/2022-gartner-mq-gated.html
To learn more about application security from Veracode, please visit: https://www.veracode.com/products
1
Gartner, “Magic Quadrant for Application Security Testing” by Dale Gardner, Mark Horvath, Dionisio Zumerle, 18 April 2022.
2
Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, 27 October 2021.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner and Peer Insights are trademarks of Gartner, Inc. and/or its affiliates. All rights reserved. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com , on the Veracode blog and on Twitter .
Copyright © 2022 Veracode, Inc. All rights reserved. All other brand names, product names, or trademarks belong to their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005866/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom